KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Revenue (2019 - 2025)

Historic Revenue for Esperion Therapeutics (ESPR) over the last 7 years, with Q3 2025 value amounting to $87.3 million.

  • Esperion Therapeutics' Revenue rose 6909.86% to $87.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $303.8 million, marking a year-over-year increase of 282.65%. This contributed to the annual value of $332.3 million for FY2024, which is 18565.51% up from last year.
  • As of Q3 2025, Esperion Therapeutics' Revenue stood at $87.3 million, which was up 6909.86% from $82.4 million recorded in Q2 2025.
  • In the past 5 years, Esperion Therapeutics' Revenue ranged from a high of $137.7 million in Q1 2024 and a low of $8.0 million during Q1 2021
  • Over the past 5 years, Esperion Therapeutics' median Revenue value was $32.2 million (recorded in 2023), while the average stood at $44.1 million.
  • In the last 5 years, Esperion Therapeutics' Revenue tumbled by 8084.26% in 2021 and then surged by 46613.51% in 2024.
  • Quarter analysis of 5 years shows Esperion Therapeutics' Revenue stood at $15.4 million in 2021, then grew by 22.19% to $18.8 million in 2022, then surged by 71.38% to $32.2 million in 2023, then soared by 114.3% to $69.1 million in 2024, then grew by 26.33% to $87.3 million in 2025.
  • Its last three reported values are $87.3 million in Q3 2025, $82.4 million for Q2 2025, and $65.0 million during Q1 2025.